May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
VEGF Is Required for Neuroretina Survival and Function
Author Affiliations & Notes
  • A. S. Maharaj
    Pathology and Ophthalmology, Harvard Medical School and Schepens Eye Research Institute, Boston, Massachusetts
  • M. Saint-Geniez
    Pathology and Ophthalmology, Harvard Medical School and Schepens Eye Research Institute, Boston, Massachusetts
  • T. E. Walshe
    Pathology and Ophthalmology, Harvard Medical School and Schepens Eye Research Institute, Boston, Massachusetts
  • E. Sekiyama
    Pathology and Ophthalmology, Harvard Medical School and Schepens Eye Research Institute, Boston, Massachusetts
  • T. Kurihara
    Pathology and Ophthalmology, Harvard Medical School and Schepens Eye Research Institute, Boston, Massachusetts
  • B. Tucker
    Pathology and Ophthalmology, Harvard Medical School and Schepens Eye Research Institute, Boston, Massachusetts
  • M. Young
    Pathology and Ophthalmology, Harvard Medical School and Schepens Eye Research Institute, Boston, Massachusetts
  • P. A. D'Amore
    Pathology and Ophthalmology, Harvard Medical School and Schepens Eye Research Institute, Boston, Massachusetts
  • Footnotes
    Commercial Relationships  A.S. Maharaj, None; M. Saint-Geniez, None; T.E. Walshe, None; E. Sekiyama, None; T. Kurihara, None; B. Tucker, None; M. Young, None; P.A. D'Amore, None.
  • Footnotes
    Support  NIH Grants EY05318, EY015435 and CA45548 to P.A.D
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 5836. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A. S. Maharaj, M. Saint-Geniez, T. E. Walshe, E. Sekiyama, T. Kurihara, B. Tucker, M. Young, P. A. D'Amore; VEGF Is Required for Neuroretina Survival and Function. Invest. Ophthalmol. Vis. Sci. 2008;49(13):5836.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Agents targeting VEGF have led to significant vision improvements in many patients with wet macular degeneration. However, the role of VEGF in the adult retina remains undefined. The goal of these studies was to investigate the effect of VEGF neutralization on the structure and function of the normal, adult retina.

Methods: : VEGF and its receptors were localized in adult retina using VEGF-lacZ/+ and VEGFR2-lacZ/+ mice as well as by immunohistochemistry. Expression of VEGF in isolated Müller cells was examined by PCR and western-blot analysis. VEGFR2 activation was examined by immunoprecipitation with antiVEGFR2 followed by Western blotting with anti-phosphotyrosine. Systemic VEGF neutralization was accomplished by adenoviral delivery of sFlt1. Vascular changes were assessed by fundus angiography, FITC-dextran perfusion and TEM. Retinal cell apoptosis was determined by TUNEL and the thickness of the inner nuclear (INL) and outer nuclear layers. Visual function was measured by electrogram (ERG). A role for VEGF autocrine signaling in Müller cell survival was investigated in vitro using VEGF siRNA in Müller cells (M10M1).

Results: : VEGF was expressed by astrocytes and pericytes in the ganglion cell layer and in the INL, and VEGFR2 was demonstrated to be phosphorylated in the adult retina by immunoprecipitation with anti-VEGFR2 and blotting with anti-phosphotyrosine. After 14 days of VEGF neutralization, while there was no detectable effect on the vasculature of the INL, there was marked apoptosis of cells in the INL and photoreceptors, leading to reduced inner and outer nuclear layer thickness. Four weeks of VEGF neutralization led to visual dysfunction as evidenced as reduced a- and b-waves in ERGs. siRNA suppression of VEGF expression in Müller cells led to the induction of the pro-apoptotic gene bax and increased apoptosis.

Conclusions: : These data implicate VEGF in the maintenance of neural retina structure and function, and point to a need for caution in the prolonged use of intraocular anti-VEGF therapy.

Keywords: vascular endothelial growth factor • retina • pathology: experimental 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×